uniQure (NASDAQ:QURE) Coverage Initiated by Analysts at Chardan Capital

Stock analysts at Chardan Capital began coverage on shares of uniQure (NASDAQ:QURE) in a research report issued on Tuesday, Marketbeat reports. The brokerage set a “buy” rating and a $38.00 price target on the biotechnology company’s stock. Chardan Capital’s target price would suggest a potential upside of 257.82% from the stock’s current price.

Several other equities analysts have also recently commented on QURE. Cantor Fitzgerald boosted their price objective on shares of uniQure from $28.00 to $58.00 and gave the company an “overweight” rating in a research note on Tuesday, December 10th. Guggenheim restated a “buy” rating on shares of uniQure in a research report on Wednesday, December 11th. The Goldman Sachs Group upped their price target on shares of uniQure from $9.00 to $20.00 and gave the stock a “neutral” rating in a report on Thursday, December 12th. Royal Bank of Canada reissued an “outperform” rating and set a $24.00 price objective on shares of uniQure in a research note on Tuesday, January 21st. Finally, Leerink Partners upped their target price on uniQure from $26.00 to $44.00 and gave the stock an “outperform” rating in a research note on Wednesday, December 11th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $38.80.

uniQure Stock Up 7.2 %

QURE stock opened at $10.62 on Tuesday. The stock has a 50-day simple moving average of $13.50 and a two-hundred day simple moving average of $10.89. uniQure has a twelve month low of $3.73 and a twelve month high of $19.18. The firm has a market capitalization of $574.30 million, a PE ratio of -2.14 and a beta of 0.37. The company has a quick ratio of 6.51, a current ratio of 6.51 and a debt-to-equity ratio of 0.92.

Insider Buying and Selling at uniQure

In other uniQure news, CEO Matthew C. Kapusta sold 6,717 shares of uniQure stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $11.32, for a total value of $76,036.44. Following the transaction, the chief executive officer now directly owns 580,795 shares of the company’s stock, valued at $6,574,599.40. The trade was a 1.14 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Christian Klemt sold 14,341 shares of the stock in a transaction on Tuesday, February 25th. The shares were sold at an average price of $10.70, for a total transaction of $153,448.70. Following the sale, the chief financial officer now directly owns 152,372 shares of the company’s stock, valued at $1,630,380.40. The trade was a 8.60 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 90,830 shares of company stock worth $961,401 over the last three months. Company insiders own 4.74% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. Avoro Capital Advisors LLC purchased a new stake in uniQure in the 4th quarter worth approximately $38,410,000. Franklin Resources Inc. purchased a new stake in uniQure in the third quarter worth $7,360,000. RTW Investments LP boosted its holdings in uniQure by 8,936.3% in the fourth quarter. RTW Investments LP now owns 903,625 shares of the biotechnology company’s stock valued at $15,958,000 after acquiring an additional 893,625 shares in the last quarter. Point72 Asset Management L.P. increased its position in uniQure by 81.3% during the 4th quarter. Point72 Asset Management L.P. now owns 1,771,352 shares of the biotechnology company’s stock valued at $31,282,000 after purchasing an additional 794,459 shares during the period. Finally, Boxer Capital Management LLC bought a new position in uniQure in the 4th quarter worth $13,245,000. Hedge funds and other institutional investors own 78.83% of the company’s stock.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.